Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients

NACompletedINTERVENTIONAL
Enrollment

1,206

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

August 31, 2020

Study Completion Date

August 30, 2021

Conditions
Anterior Myocardial InfarctionHeart Failure
Interventions
DRUG

intravenous Placebo

Patients receive intravenous Placebo (saline) injection

DRUG

Metoprolol Injectable Product

Patients receive intravenous Metoprolol injection

DEVICE

Romote Ischemic Conditioning (RIC)

Patients receive RIC treatment

COMBINATION_PRODUCT

Metoprolol & RIC

Patients receive Metoprolol \& RIC treatment

Trial Locations (16)

100044

Peking Univerisity People'Hospital, Beijing

130000

The Second Hospital of Jilin University, Changchun

163001

Daqing Oilfield General Hospital, Daqing

210009

Zhongda Hospital Southeast University, Nanjing

330006

The Second Affiliated Hospital of Nanchang University, Nanchang

Unknown

Beijing Chao-Yang Hospital, Capital Medical University, Beijing

Guangdong general hospital, Guangzhou

Second hospital of hebei medical university, Shijiazhuang

The first affiliated hospital of Zhengzhou medical university, Zhengzhou

the second affiliated hospital of Dalian medical university, Dalian

Shenyang military district general hospital of the people's liberation army, Shenyang

The first affiliated hospital of military medical university, Xi’an

Third Military Medical University, Chongqing

The General Hospital of Tianjin Medical University, Tianjin

Tianjin Chest Hospital, Tianjin

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

All Listed Sponsors
collaborator

Beijing Chao Yang Hospital

OTHER

lead

Harbin Medical University

OTHER

NCT03579914 - Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients | Biotech Hunter | Biotech Hunter